Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of BTK inhibitor PCI-32765 when
given together with rituximab and bendamustine hydrochloride in treating patients with
recurrent non-Hodgkin lymphoma (NHL). BTK inhibitor PCI-32765 may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as
rituximab, can block cancer growth in different ways. Some block the ability of cancer to
grow and spread. Others find cancer cells and help kill them or carry cancer-killing
substances to them. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving BTK inhibitor PCI-32765 together with rituximab and bendamustine
hydrochloride may kill more cancer cells.